Q32 Bio (QTTB) Convertible Debt (2023)

Q32 Bio (QTTB) recorded quarterly Convertible Debt of $38.6 million in Q4 2023.

Q32 Bio (QTTB) Convertible Debt (2023) Analysis & Trends

Q32 Bio's Convertible Debt history runs 1 years deep, the most recent figure standing at $38.6 million for Q4 2023.

In Q4 2023, Convertible Debt changed N/A year-over-year to $38.6 million; the TTM figure through Dec 2023 stood at $38.6 million (changed N/A YoY), while the FY2023 annual figure was $38.6 million, changed N/A from the prior year.
Convertible Debt was $38.6 million for Q4 2023 at Q32 Bio.
In the past five years, Convertible Debt ranged from a high of $38.6 million in Q4 2023 to a low of $38.6 million in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	Q32 Bio	177.18 Mn	126.43 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2023	38.60 Mn